Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Cancer Res Clin Oncol. 2003 Jan;129(1):52-6. Epub 2003 Jan 31.

Preliminary results of radiotherapy with or without weekly paclitaxel in locally advanced non-small cell lung cancer.

Author information

  • 1Gülhane Military Medicine Academy Radiation Oncology Department, GATA Loj Ural apt Daire 39, Etlik, 06018, Ankara, Turkey. culutin@yahoo.com

Abstract

PURPOSE:

In this study our objective was to evaluate the therapeutic significance of concurrent paclitaxel and radiotherapy compared with radiotherapy alone.

PATIENTS AND METHODS:

Patients with stage III A/B NSCLC were randomly assigned to receive either radiotherapy alone (group 2) or concurrent weekly paclitaxel with radiotherapy (group 1) in GMMA. Radiotherapy was given as a split-course schedule with the total dose of 56 Gy. Paclitaxel, 60 mg/m(2), was administered only to group 1 on the first day of each radiotherapy week. To assess differences between values, P values were calculated with the chi(2) test. A Mann Whitney U-test was used to assess significant differences between the two values. Actuarial survival curves were calculated by the Kaplan-Meier method.

RESULTS:

There were 25 patients who underwent chemoradiotherapy and 26 who underwent radiotherapy only. Median follow-up was 14 months. The overall response rate was 92% and 70% for groups 1 and 2, respectively ( P= 0.003). Median survival was 15.2 months for group 1, and 12.0 months for group 2 ( P= 0.027).

CONCLUSION:

Based on this response and the toxicity profile, outpatient split-course radiotherapy and weekly paclitaxel seems to be feasible and safe.

PMID:
12618901
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer
    Loading ...
    Write to the Help Desk